Ponatinib and blinatumomab results in high rates of CMR and NGS MRD negativity in Ph-positive ALL
125 بار بازدید -
پارسال
-
Dr Nicholas Short speaks to
Dr Nicholas Short speaks to ecancer at EHA 2023 about a phase II study evaluating a chemotherapy-free combination of ponatinib and blinatumomab for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia.
He reports that all patients responded and the combination saw very high rates of MRD negativity.
Dr Short explains that only 1 out of the 60 treated patients underwent a transplant meaning that it can also be a regimen that overcome the need for transplant.
He reports that all patients responded and the combination saw very high rates of MRD negativity.
Dr Short explains that only 1 out of the 60 treated patients underwent a transplant meaning that it can also be a regimen that overcome the need for transplant.
پارسال
در تاریخ 1402/04/15 منتشر شده
است.
125
بـار بازدید شده